RemeGen Co News

News

Ticker

688331.SS

ISIN

CNE100005B03

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

RemeGen Co Eulerpool News

April 29

RemeGen's Strategic Focus on Domestic Growth Signals Strong Future Prospects

RemeGen Co Stock News

RemeGen Co is being monitored by journalists and investors worldwide. We gather the latest RemeGen Co news here.

January 5·
Yahoo
Asian Growth Companies With High Insider Ownership In January 2026
November 28·
Yahoo
Asian Market Value Picks Featuring 3 Stocks Trading Below Estimated Worth
November 20·
Yahoo
Asian Growth Companies With Strong Insider Confidence November 2025
September 18·
Benzinga
Reported Earlier, RemeGen Announces Oral Presentation Of Phase III Telitacicept Study Results For Generalized Myasthenia Gravis At AANEM 2025
August 19·
Yahoo
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
August 14·
Yahoo
Asian Growth Stocks With Insider Ownership Expecting Up To 93% Earnings Growth
July 17·
Yahoo
Asian Growth Companies With High Insider Ownership For July 2025
June 24·
Yahoo
Asian Value Stock Picks For June 2025
June 16·
Yahoo
Asian Growth Stocks Insiders Own With Up To 32% Return On Equity
June 3·
Yahoo
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
May 16·
Yahoo
High Growth Tech Stocks in Asia for May 2025
May 9·
SeekingAlpha
Biotech Outperformance - Can't Take What's Already Earned
April 17·
Yahoo
High Growth Tech Stocks In Asia For April 2025
April 2·
Yahoo
3 Asian Stocks That May Be Trading Below Intrinsic Value By Up To 49%
March 20·
Yahoo
Asian Growth Companies With High Insider Ownership For March 2025
January 21·
Yahoo
3 Growth Companies With High Insider Ownership To Watch
January 20·
Yahoo
High Growth Tech Stocks To Watch In January 2025
January 8·
Yahoo
Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
December 20·
Yahoo
High Growth Tech Stocks To Watch In December 2024
November 21·
Yahoo
High Growth Tech Stocks And 2 More Exciting Picks For Your Portfolio

RemeGen Co Stock Press Releases

RemeGen Co regularly publishes news on the company's website that are relevant for investors.

RemeGen Co News 2026

This page contains all current news, analysis and press releases for RemeGen Co stock (688331.SS, ISIN: CNE100005B03). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at RemeGen Co.

RemeGen Co Stock

RemeGen Co RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings.